LifeMD faces a class action lawsuit after disclosing disappointing second-quarter 2025 results and reducing its financial outlook. Shares plummeted 44% from earlier expectations, prompting Hagens Berman to investigate potential securities law violations. The suit covers investors who bought LifeMD securities between May 7 and August 5, 2025.